SomnoMed's New Era: Single CEO, Virtus Launch, and a European Reckoning
SomnoMed (SOM.AX), the $73M micro-cap oral appliance leader, delivered a solid FY26 but one that hinted at a strategic inflection point. Headline figures showed revenue up 3% to $114.5M, EBITDA up 19% to $10.9M, and margin expansion to 9.6% — a testament to cost discipline. Yet the real story lies in the leadership transition to a single CEO, the controlled release of Virtus, and a European market that is increasingly difficult to navigate.
Financial discipline amid a tale of two halves
The year was marked by stark regional contrasts. As CFO Ye-Fei Guo noted, “In a tale of 2 halves, the second half revenue was down by 7% or less than 1% in constant currency, impacted by a change in European market dynamics and the significant appreciation of the Australian dollar against our key currencies.” — Ye-Fei Guo, CFO · 2026-08-27 North America, however, proved resilient, growing 11% on a constant currency basis, while Europe, the most mature region, saw second-half pressures from reimbursement and referral path changes. The company has responded by restructuring European leadership and sharpening product strategies.
Leadership and product pipeline: a new chapter
The appointment of Karen Borg as sole CEO after Amrita Blickstead's departure marks a strategic consolidation. “EBITDA increased 19% to $10.9 million with EBITDA margin improving to 9.6%,” — Karen Borg, CEO · 2026-08-27 she reported, setting the stage for a renewed growth push. Key product catalysts include oral appliance innovation, particularly Virtus, targeted at the large bruxism comorbidity, and the long-awaited Connected Care (Rest Assure) platform. Initial Virtus feedback is encouraging; a clinician recounted that a patient who previously broke a new appliance every six months now may not need that constant replacement.
And more importantly, their clinicians have said – and I can say anecdotally, one clinician actually said to me that their patient was literally going through products, a new product every 6 months. And they've had this product now, and it looks like they may not be coming back every 6 months.
On Rest Assure, CEO Karen Borg confirmed FDA approval for the compliance component and is working through the AHI requirements. The company will share a fuller strategy at the upcoming AGM in November.
Strategic pivot: toward growth and innovation
The broader narrative is a pivot from turnaround to growth. The company is investing heavily in product development and customer expansion, with “Up to 50% of CPAP patients discontinue therapy, creating a significant opportunity for oral appliance alternatives.” — Karen Borg, CEO · 2026-08-27 This aligns with the global theme of GLP 1 therapies expanding the patient pool. Management's FY27 guidance of high single-digit revenue growth and stable EBITDA margins signals confidence but also prudence, with more detail promised at the AGM.
Notably, the company is also addressing a key European market reimbursement application, which could unlock future growth. The strategic emphasis on reimbursed environment is clear, as the company navigates varying access pathways across regions.
In a busy reporting day, SomnoMed's story stands out for its decisive leadership change and product pipeline momentum. The market will watch closely to see if the new focus on Connected Care, combined with Virtus adoption, can drive the double-digit growth targeted by FY30.